Illumina Stock Rises After Sale of Grail
After over two years of antitrust battles, Illumina Inc (NASDAQ:ILMN) will sell its cancer diagnostic test maker Grail through a third-party sale of capital markets transaction by the second quarte...
3 Charts For Investors to Watch Monday: Illumina, Roku, Bitcoin
Here's our daily look at three charts connected to recent news-driven price moves, with key technical levels to monitor.
Illumina shares rally as it puts Grail up for sale
Illumina Inc (NASDAQ:ILMN) stock traded on the front foot, up 5.6% to $134.25, after the company told investors it will seek a sale of its gene sequencing business Grail. It comes after European an...
Illumina to Sell Grail. It's Giving Up on its Biotech Antitrust Battle.
The decision shows the company didn't see a way to overcome regulators' objections.
Illumina to divest cancer test maker Grail
The divestiture will be executed through a third-party sale or capital markets transaction, San Diego-based Illumina said in a statement, adding that it would finalize the terms by second quarter o...
Illumina To Sell Grail After U.S. Antitrust Ruling
Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws,
Court Sides With FTC Finding Illumina-Grail Deal Anticompetitive
Judges also fault agency for not properly considering Illumina's plan to fix drawbacks.
Illumina: Grail's Divestment Could Unlock Significant Shareholder Value
Illumina's market cap has fallen 80% from its all-time highs in 2021, but the divestment of Grail could bring it back on track. Illumina's competitive advantage lies in its scalable DNA sequencing ...
Illumina's fight with EU regulators over $7.1B Grail acquisition rages on
Illumina Inc (NASDAQ:ILMN), a genetic testing company, accused European Union antitrust1B regulators of overreach in their decision to stop its $7.1 billion acquisition of cancer detection test co...
Illumina files registration statement for potential Grail divestiture
Illumina said on Monday it had filed a registration statement with the U.S. securities regulator related to a potential divestiture of Grail , even as it challenges a European Union order to divest...
Illumina (ILMN) Expands Globally Despite Macroeconomic Woes
The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.
Illumina, Inc. (ILMN) Piper Sandler 35th Annual Healthcare Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 11:30 AM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants...
Illumina, Inc. (ILMN) Evercore ISI 6th Annual HealthCONx Conference
Illumina, Inc. (NASDAQ:ILMN ) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Joydeep Goswami - Chief Financial Officer Salli Schwartz - Vice Presid...
Illumina (ILMN) Launches Initiative on Pathogen Sequencing
Illumina (ILMN) introduces a new initiative to drive more equitable access to genomics globally.
As Illumina stock bounces off a 10-year low, analysts see no quick fix
As shares of Illumina Inc. ILMN, +5.46% trade near 10-year lows, analysts are reining in expectations for the DNA-sequencing company.
Related Companies